Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21779018 | 1.00 | PNP (0.55) | PNPCYP3A4MAPTADRB1DNMT1 | |
| SCHEMBL114652 | 1.00 | PNP (0.55) | PNPCYP3A4MAPTADRB1DNMT1 | |
| Phosphoric Acid SCHEMBL9013988 | 0.96 | PNP (0.52) | PNPCYP3A4MAPTADRB1DNMT1 | |
| SCHEMBL655857 | 0.90 | PNP (0.65) | PNPCYP3A4MAPTADRB1DNMT1 | |
| SCHEMBL655858 | 0.90 | PNP (0.65) | PNPCYP3A4MAPTADRB1DNMT1 | |
| Citric Acid SCHEMBL3066161 | 0.89 | PNP (0.46) | PNPCYP3A4MAPTADRB1DNMT1 | |
| SCHEMBL3868526 | 0.88 | PNP (0.54) | PNPCYP3A4MAPTADRB1DNMT1 | |
| SCHEMBL13351290 | 0.88 | PNP (0.54) | PNPCYP3A4MAPTADRB1DNMT1 | |
| SCHEMBL18723297 | 0.88 | PNP (0.54) | PNPCYP3A4MAPTADRB1DNMT1 | |
| SCHEMBL14543297 | 0.88 | PNP (0.54) | PNPCYP3A4MAPTADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634399-A1 | MAMMALIAN SPERMATOZOA DNA INTEGRITY TESTING VIA EVALUATION OF ITS 8-OXODG CONTENT | Université Clermont Auvergne (FR) | 2025-10-22 | — | — | EP | claimed |
| US-20250288555-A1 | SYSTEMS AND METHODS TO IMPROVE EXERCISE TOLERANCE | EPICENTRX, INC. (US) | 2025-09-18 | — | — | US | claimed |
| US-12359000-B2 | Anti-8-hydroxy-2′-deoxyguanosine antibody or antibody fragment thereof, production method, kit, measuring method, and device for measurement | TDK CORPORATION (JP) | 2025-07-15 | — | — | US | claimed |
| US-12352695-B2 | System and method for monitoring the health of dialysis patients | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2025-07-08 | — | — | US | claimed |
| EP-4553065-A2 | NOVEL COMPOUNDS FOR TREATING MITOCHONDRIAL DISEASE | KHONDRION IP B.V. (NL) | 2025-05-14 | — | — | EP | claimed |
| EP-4551234-A1 | REDOX-MODULATING ORGANELLE COMPLEXES | LUCA Science Inc. (JP) | 2025-05-14 | — | — | EP | claimed |
| WO-2025076473-A1 | PROTEINS BISPECIFIC TO CD3 AND NKG2DL AND ASSOCIATED USES THEREOF | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-10 | — | — | WO | claimed |
| WO-2024254556-A9 | BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS | ATOSSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2024254556-A1 | BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS | ATOSSA THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240280590-A1 | COMPOSITIONS AND METHODS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY BIOMARKER DETECTION | UNIVERSITY OF WASHINGTON (US) | 2024-08-22 | — | — | US | claimed |
| US-20060281809-A1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2006-12-14 | — | — | US | claimed |
| WO-2006130775-A2 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMAKERS | EDISON PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | WO | claimed |
| US-20060105384-A1 | Detection of DNA damage | DIONEX CORPORATION | 2006-05-18 | — | — | US | claimed |
| US-20060099634-A1 | Simplified biological evaluation method of natural and artificial chemicals by using DNA injury index and apparatus therefor | ECOLOGICAL TECHNOLOGY RESEARCH, LTD. (JP) | 2006-05-11 | — | — | US | claimed |
| US-20050112572-A1 | Detecting oxidation stresses in sampling using markers; measurement; calibration | PROBIOX SA (BE) | 2005-05-26 | — | — | US | claimed |
| EP-1423518-A2 | PROCESS FOR THE DETECTION OF OXIDATIVE STRESS AND KIT FOR ITS IMPLEMENTATION | Probiox SA (BE) | 2004-06-02 | — | — | EP | claimed |
| US-20030186260-A1 | Simple method of biologically evaluating natural and artificial chemicals by using dna injury index and apparatus therefor | ECOLOGICAL TECHNOLOGY RESEARCH, LTD. (JP) | 2003-10-02 | — | — | US | claimed |
| US-6548252-B1 | Electrochemically analyzing samples from selected areas of the body of a living organism for elevated free levels of nucleotide excision products resulting from DNA or RNA damage | ESA, INC. | 2003-04-15 | — | — | US | claimed |
| WO-2003016527-A2 | PROCESS FOR THE DETECTION OF OXIDATIVE STRESS AND KIT FOR ITS IMPLEMENTATION | PROBIOX SA (BE) | 2003-02-27 | — | — | WO | claimed |
| EP-1267162-A1 | SIMPLE METHOD OF BIOLOGICALLY EVALUATING NATURAL AND ARTIFICIAL CHEMICALS BY USING DNA INJURY INDEX AND APPARATUS THEREFOR | Ecological Technology Research, Ltd. (JP) | 2002-12-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288555-A1 | SYSTEMS AND METHODS TO IMPROVE EXERCISE TOLERANCE | SPR, GYS1, PYGM | PNP 857/4885CYP3A4 889/4885MAPT 4863/4885 |
| US-20060281809-A1 | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | ECHS1, FH, ACAA2 | PNP 3872/4885CYP3A4 4235/4885MAPT 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.